ViroPharma's Antivirus Fails Study By: MarketMinute.com Stock News February 09, 2009 at 12:52 PM EST ViroPharma Inc. (Nasdaq: VPHM) reported that its antivirus maribavir failed a late stage clinical trial sending shares of the biopharmaceutical plummeting $5.91 to $6.30.